Major U.S. equities indexes ticked higher as the latest Consumer Price Index (CPI) data revealed that inflation cooled slightly more than expected. The key inflation gauge rose 2.9% over the year in July, a slight downtick from the previous month.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

We have narrowed our search to five P&C insurers with strong potential for the rest of 2024. These are: ACGL, ALL, PGR, RLI, ROOT.

MAYFIELD VILLAGE, OHIO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- The Progressive Corporation (NYSE:PGR) today reported the following results for the month ended July 31, 2024:

41% Growth in 340B Contract Service Revenue and Momentum in Prescription Volumes Drive Positive Cashflow from Operations MIAMI , Aug. 14, 2024 /PRNewswire/ -- Progressive Care Inc. (OTCQB: RXMD) ("Progressive Care" or the "Company"), a personalized healthcare services and technology provider, today announced financial results for its second quarter of 2024. The Company reported second quarter revenues of approximately $13.5 million, a 17% increase compared to revenues reported in the second quarter of 2023.

It has been a rather wild few weeks in the market, with the broad stock indexes experiencing the sharpest correction so far this year. Although stocks have bounced back aggressively following last week's sell off, there is still some uncertainty on the horizon.

Progressive (PGR) seems well-poised on improving premiums, steady policy life expectancy, investment in technology and a solid capital position.

The application was evaluated based on the positive clinical outcomes in patients treated in Germany under the named-patient program The Regenerative Medicine Advanced Therapies designation allows Kyverna to leverage on more expedited meetings and more senior FDA leadership involvement throughout the development cycle for KYV-101 EMERYVILLE, Calif. , Aug. 12, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today the designation as Regenerative Medicine Advanced Therapy (RMAT) by the U.S. Food and Drug Administration (FDA) for its autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate, KYV-101, to be used for the treatment of patients suffering from progressive myasthenia gravis.

Seasonal trading can be a benefit in stock selection. For an unknown reason, some equities perform well in some parts of the year and poorly in other parts of the year.

Five old economy stocks with strong near-term potential are: NEM, GE, PFE, PGR, BSX.

Investors looking for stocks in the Insurance - Property and Casualty sector might want to consider either Skyward Specialty Insurance (SKWD) or Progressive (PGR). But which of these two stocks is more attractive to value investors?

Recently, Zacks.com users have been paying close attention to Progressive (PGR). This makes it worthwhile to examine what the stock has in store.